Anixa Biosciences Accounts Payables 2011-2026 | ANIX

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Anixa Biosciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
165 K	525 K	206 K	265 K	136 K	232 K	586 K	582 K	480 K	373 K	375 K	540 K	527 K	305 K	375 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
586 K	136 K	378 K

Quarterly Accounts Payables Anixa Biosciences

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
148 K	165 K	276 K	284 K	-	525 K	302 K	215 K	364 K	206 K	94 K	195 K	504 K	265 K	227 K	93 K	512 K	136 K	208 K	136 K	367 K	232 K	232 K	232 K	613 K	586 K	586 K	586 K	417 K	582 K	582 K	582 K	541 K	480 K	480 K	480 K	560 K	373 K	373 K	373 K	578 K	375 K	375 K	375 K	492 K	540 K	540 K	540 K	489 K	527 K	527 K	527 K	449 K	305 K	305 K	305 K	-	375 K	375 K	375 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
613 K	93 K	388 K

Accounts Payables of other stocks in the Diagnostics research industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
Aspira Women's Health AWH	1.24 M	-	-6.19 %	$ 10.5 M	USA
Agilent Technologies A	446 M	$ 116.52	2.33 %	$ 35.4 B	USA
Biocept BIOC	1.52 M	-	-13.05 %	$ 7.29 M	USA
DermTech DMTK	1.48 M	-	-11.32 %	$ 2.94 M	USA
BioNano Genomics BNGO	5.59 M	$ 1.19	1.28 %	$ 6.48 M	USA
Enzo Biochem ENZ	1.38 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	176 M	-	-	$ 19.8 B	USA
Interpace Biosciences IDXG	983 K	$ 1.91	-4.44 %	$ 8.45 M	USA
CareDx, Inc CDNA	9.99 M	$ 17.7	0.17 %	$ 943 M	USA
Akumin AKU	36.6 M	-	-17.87 %	$ 25.9 M	Canada
Heska Corporation HSKA	16.4 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	1.16 M	-	-20.0 %	$ 1.06 M	USA
Co-Diagnostics CODX	1.88 M	$ 4.4	101.83 %	$ 5.85 M	USA
Burning Rock Biotech Limited BNR	63.1 M	$ 15.99	-0.62 %	$ 172 M	China
Castle Biosciences CSTL	6.9 M	$ 24.93	0.4 %	$ 692 M	USA
Accelerate Diagnostics AXDX	4.5 M	-	-61.36 %	$ 2.46 M	USA
Global Cord Blood Corporation CO	8.33 M	-	-	$ 399 M	China
Charles River Laboratories International CRL	149 M	$ 175.31	3.36 %	$ 8.69 B	USA
Danaher Corporation DHR	1.84 B	$ 196.21	2.72 %	$ 140 B	USA
DexCom DXCM	344 M	$ 65.46	3.72 %	$ 25.5 B	USA
OpGen OPGN	245 K	-	-16.95 %	$ 1.54 M	USA
PerkinElmer PKI	185 M	-	-0.91 %	$ 14.7 B	USA
Fulgent Genetics FLGT	18.4 M	$ 15.87	-0.25 %	$ 480 M	USA
Quotient Limited QTNT	4.66 M	-	-11.32 %	$ 1.1 M	Schweiz
Guardant Health GH	54.4 M	$ 92.47	-0.89 %	$ 11.6 B	USA
QIAGEN N.V. QGEN	72.7 M	-	-	$ 10.6 B	Niderland
Biomerica BMRA	295 K	$ 2.18	0.93 %	$ 5.01 M	USA
ICON Public Limited Company ICLR	173 M	$ 107.91	0.7 %	$ 8.9 B	Irlanda
Check-Cap Ltd. CHEK	952 K	-	-	$ 9.42 M	Israel
Illumina ILMN	221 M	$ 128.62	1.72 %	$ 20.5 B	USA
Celcuity CELC	6.41 M	$ 116.36	0.69 %	$ 5.44 B	USA
Laboratory Corporation of America Holdings LH	841 M	$ 275.47	2.34 %	$ 22.9 B	USA
Lantheus Holdings LNTH	42.9 M	$ 80.04	2.51 %	$ 5.4 B	USA
Chembio Diagnostics CEMI	3.34 M	-	0.22 %	$ 16.8 M	USA
Quest Diagnostics Incorporated DGX	307 M	$ 198.5	0.87 %	$ 22 B	USA
Mettler-Toledo International MTD	267 M	$ 1 320.7	3.99 %	$ 27.2 B	Schweiz
Myriad Genetics MYGN	30 M	$ 4.72	-0.32 %	$ 437 M	USA
ENDRA Life Sciences NDRA	383 K	$ 5.04	-5.62 %	$ 3.97 M	USA
Neogen Corporation NEOG	79.6 M	$ 10.29	3.06 %	$ 2.23 B	USA
National Research Corporation NRC	1.17 M	$ 17.53	2.88 %	$ 392 M	USA
Natera NTRA	31.1 M	$ 211.52	1.08 %	$ 20.8 B	USA
Pacific Biosciences of California PACB	20.8 M	$ 1.45	0.35 %	$ 435 M	USA